For Immediate Release
Chicago, IL – March 10, 2010 – Today Zacks.com features the Top 5 Health Care funds: Franklin Biotechnology Discovery A (FBDIX), ICON Healthcare (ICHCX), Manning & Napier Life Sciences (EXLSX), Rydex Biotechnology (RYOIX) and Fidelity Select Medical Equipment & Systems (FSMEX).
These healthcare funds are given our highest rating; Zacks #1 Ranked Strong Buys. That means we expect these funds to outperform their peers in the future.
Zacks.com provides exclusive ratings on over 18,000 funds in 42 different categories. To learn more about Zacks Mutual Fund Rank, click here. http://at.zacks.com/?id=6760
Zacks #1 Ranked Health Care Funds
Franklin Biotechnology Discovery A (FBDIX) seeks long-term capital growth. It invests the majority of its assets in biotechnology and discovery research companies. It may also invest up to 20% of its assets in debt and equities worldwide. The healthcare fund returned 12.62% over the last one year period.
The Fund Manager is Evan S. McCulloch and he has managed this healthcare fund since 1997.
ICON Healthcare (ICHCX) invests at least 80% of its assets in healthcare companies which are traded in U.S. markets. It invests in common and preferred stocks of companies with a wide range of market capitalizations. It is a no load fund and is non-diversified.
The healthcare fund returned 22.85% in 2009 and has a ten year annualized return of 5.17%.
Manning & Napier Life Sciences (EXLSX) seeks capital appreciation by investing the heavily in the life sciences sector. Domestic and foreign equity, ADRs and dollar denominated foreign securities make up the majority of its assets. The healthcare fund has a five year annualized return of 6.63%.
This healthcare fund has a minimum initial investment of $2,000 and an expense ratio of 1.12% compared to a category average of 1.91%.
Rydex Biotechnology (RYOIX) invests substantially in equity securities and derivatives issued by domestic biotechnology companies. It is non-diversified and seeks long-term capital growth. The healthcare fund returned 25.06% in 2009 has a five year annualized return of 6.02%.
Michael P. Byrum is the fund manager and he has managed this healthcare fund since 1998.
Fidelity Select Medical Equipment & Systems (FSMEX) seeks capital growth. It invests primarily in companies whose principal operations are related to medical equipment, devices and related technologies. The healthcare fund has a ten year annualized return of 9.71%.
As of January 2010, this healthcare fund held 60 issues, with 12.81% of its total assets invested in Covidien, Ltd.
About Zacks Mutual Fund Rank
The Zacks Mutual Fund Rank is a quantitative ratings system created by Len Zacks, a PHD in mathematics from MIT. The goal of the rank is simple; goal to help investors find the best mutual funds to beat the market.
To discover how the Zacks mutual fund rank works and to receive daily notifications on our fund rankings, click here: http://at.zacks.com/?id=5855
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms. It monitors more than 200,000 earnings estimates, looking for changes.
Then when changes are discovered, they’re applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell and #5 Strong Sell. This proprietary stock picking system; the Zacks Rank, continues to outperform the market by nearly a 3 to 1 margin.
To discover all Zacks has to offer investors like yourself, then go to our home page at www.zacks.com
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9149
Email: pr@zacks.com
Visit: www.zacks.com
